A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer Clinical Trial

Official title:

A Phase II Clinical Study of SHR3680 Combined With SHR3162 in the Treatment of Metastatic Castration-resistant Prostate Cancer Previously Treated With Abiraterone and Docetaxel

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04102124
• Other study ID #: SHR3680-SHR3162-II-CRPC
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 8, 2019
• Est. completion date: November 1, 2022

Study information

• Verified date: May 2020
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's overall survival (OS) is superior to placebo.

Description:

This is a multicenter, randomized , double-blind Phase II trial and the aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With Abiraterone and Docetaxel whether the patient's overall survival (OS) is superior to placebo. The Stage I part is a dose-escalation and -expansion study. Approximately 18~24 patients in Stage I will receive fixed-dose of orally SHR3680 and only one of two dose levels of orally SHR3162. The Primary endpoints of the Stage I are incidence of adverse events(AE) and recommended phase 2 dose(RP2D). The Stage II part is a randomized , double-blind study. Approximately 90~120 patients in Stage II will receive SHR3162 combined with SHR3680, in which one fixed-dose levels of SHR3162 will be selected based on the result of the Stage I.The Primary endpoint of the Stage II is overall survival(OS).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 144
• Est. completion date: November 1, 2022
• Est. primary completion date: November 1, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically confirmed prostate cancer; does not suggest neuroendocrine or small cell characteristics

2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1;

3. Radiographic evidence of metastasis;

4. Sustained therapy of luteinizing hormone-releasing hormone analogue(LHRHA)or received bilateral orchiectomy; patients who did not receive bilateral orchiectomy are willing to receive sustained therapy of LHRHA;

5. Evidence of prostate cancer progression under the sustained therapy of LHRHA or bilateral orchiectomy;

6. Adequate hepatic, renal, heart, and hematological functions;

7. Patients have given voluntary written informed consent before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

8. Patient has been treated with Abiraterone and treatment failed(Treatment failure is defined as the progression of disease during treatment)

9. Patient has been treated with Docetaxel and treatment failed or can not tolerate docetaxel chemotherapy or patients who are not suitable for docetaxel treatment at the time of screening.

Exclusion Criteria:

1. Have received any anti-tumor therapy in the past 4 weeks,including radiotherapy, chemotherapy, operation, targeted therapy, immuntherapy, and endocrinotherapy;

2. Planned to initiate any other anti-tumor therapies during the study;

3. Unable to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption;

4. Clinically significant cardiovascular diseases;

5. History of seizure or certain conditions that may predispose to seizure;

6. Severe concurrent disease and infection that, in the judgment of the investigator, would make the patient inappropriate for enrollment.

Related Conditions & MeSH terms

• Castration-resistant Prostate Cancer
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• SHR3680
Tablet. Specifications of 80mg
• SHR3162
Tablet. Specifications of 10mg?40mg?50mg and 100mg
• SHR3680(Placebo)
Tablet. Specifications of 80mg
• SHR3162(Placebo)
Tablet. Specifications of 10mg?40mg?50mg and 100mg

Locations

Country	Name	City	State
China	Ye Dingwei	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Event(AE)	The type, frequency, severity, timing, seriousness, and relationship to study therapy	Approximately 70 months
Primary	Overall Survival(OS)	Time from randomisation to death due to any cause	Approximately 70 months
Secondary	Time to prostate specific antigen (PSA) progression	Time from randomisation to the first time of PSA progression according to the criterion of PCGW3	Approximately 70 months
Secondary	Radiographic Progression Free Survival(rPFS)	Time from randomisation to radiologically confirmed progressive disease or death due to any cause	Approximately 70 months
Secondary	Objective response rate (ORR)	The percentage of patients with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria	Approximately 70 months
Secondary	Time to skeletal-related events	Time from randomisation to the first occurrence of a skeletal-related event. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery.	Approximately 70 months
Secondary	PSA response rate	After the continuous therapy from randomisation to the end of the 12 weeks, the percentage of patients whose levels of PSA decreased by more than 50% compared with baseline.	Approximately 70 months
Secondary	Area Under the Curve (AUC)	The single dose and multiple dose PK will be calculated as data permits including AUC	Approximately 12 months
Secondary	Maximum Observed Plasma Concentration (Cmax)	The single-dose and multiple dose PK will be calculated as data permits including Cmax	Approximately 12 months
Secondary	Minimum Observed Plasma Concentration (Cmin)	The single-dose and multiple dose PK will be calculated as data permits including Cmin	Approximately 12 months